美国儿科抗菌药物管理计划的前性审计和反和预先授权的实施和感知有效性
Christina S Manice1,2, Nivedita Muralidhar1, Jeffrey I Campbell3,4
1Division of Pediatric Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts, USA.
Journal of the Pediatric Infectious Diseases Society
|December 18, 2023
概括
儿科抗菌药物管理计划 (ASP) 使用前性审计和反 (PAF) 和预先授权,成功程度不同. 混合方法可以最好地平衡优势和缺点,以实现最佳的抗菌药物管理.
科学领域:
- 传染性疾病 传染性疾病
- 医疗保健服务研究 医疗服务研究
- 药房实践 在药房实践.
背景情况:
- 抗微生物药物管理计划 (ASP) 对于优化抗微生物药物的使用,预防耐药性和降低医疗保健成本至关重要.
- 儿科ASP采用前性审计和反 (PAF) 和预先授权等策略来实现这些目标.
- 了解这些策略是如何实施和感知的,对于提高其有效性至关重要.
研究的目的:
- 探索在儿科抗菌药物管理计划 (ASP) 中实施前性审计和反 (PAF) 和预授权策略.
- 描述从业人员对这些选择的策略如何影响实现管理目标的看法.
- 在儿科抗菌药物管理的背景下,确定每个策略的优缺点.
主要方法:
- 与来自美国24家医院的32名儿科ASP从业者 (医生和药剂师) 进行了焦点小组.
- 组织参与者根据他们的计划的主导策略:PAF,预授权或混合方法.
- 利用应用主题分析来分析关于战略运行,理由和感知影响的开放问题,制定一个概念模型.
主要成果:
- 实践者报告了PAF和预授权策略的各种好处和局限性.
- 预期审计和反 (PAF) 识别了趋势并建立了关系,但资源密集.
- 预先授权有效制了广泛的抗生素使用,但提供了更少的教育机会.
结论:
- 儿科ASP使用PAF和预授权,重点和实施细节不同.
- 每个策略都呈现出不同的权衡,影响机组人员的满意度和感知到的效率.
- 混合方法可能允许ASP利用PAF和预授权的优势,同时减轻各自的弱点.
更多相关视频
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
7.0K
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
14.7K
相关概念视频
Healthcare Associated Infections II: Preventive Measures
2.6K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
2.6K
Pharmacovigilance
843
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
843
